Our results suggest that mt KRAS NSCLC patients might benefit from a treatment strategy that targets KRAS in combination with therapeutic agents based on pharmacogenomic markers such as SRC and BRCA1 expression levels. This evidence concerns the gene KRAS and non-small cell lung carcinoma.